# Post Approval Study of the Eversense® Continuous Glucose Monitoring

Study · id `cardio:ct-nct03908125` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03908125](<https://clinicaltrials.gov/study/NCT03908125>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03908125

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 273 participants.

## Technical summary

Registry record NCT03908125. Allocation not applicable; no masking; primary purpose diagnostic. Start 2019-03-19 (actual); primary completion 2024-02-01 (actual). Results posted on 2025-06-12.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 273 participants (enrolled count; ClinicalTrials.gov record NCT03908125, source copy `cardio:ctgov-nct03908125-2025-06-12`, retrieved 2026-10-26)
- Started: 2019-03-19 (actual) (ClinicalTrials.gov record NCT03908125, source copy `cardio:ctgov-nct03908125-2025-06-12`, retrieved 2026-10-26)
- Primary completion: 2024-02-01 (actual) (ClinicalTrials.gov record NCT03908125, source copy `cardio:ctgov-nct03908125-2025-06-12`, retrieved 2026-10-26)
- Completion: 2024-02-01 (actual) (ClinicalTrials.gov record NCT03908125, source copy `cardio:ctgov-nct03908125-2025-06-12`, retrieved 2026-10-26)
- Results first posted: 2025-06-12 (ClinicalTrials.gov record NCT03908125, source copy `cardio:ctgov-nct03908125-2025-06-12`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03908125, source copy `cardio:ctgov-nct03908125-2025-06-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03908125-2025-06-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Post Approval Study of the Eversense® Continuous Glucose Monitoring
- Acronym: PAS
- Condition: Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 1
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): Eversense® CGM System
- Lead sponsor: Senseonics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Senseonics, Inc. (`cardio:org-senseonics-inc`)

## Provenance

Content hash: 44ae49ce7d92e8e078d4d04b3057069f737b71acdca283daf9611484dfb71ee0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
